Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases

Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS [email protected] and ASRS 2021 Annual Meeting

Alliance Global Partners Biotech & Specialty Pharma Conference

Oct 13, 2021 • 3:00pm EDT

39th Annual Meeting of ASRS

Oct 9, 2021 • 8:51am - 8:55am CDT